Discovery Biology
WuXi Biology enables project teams to rapidly advance their programs from discovery stage to preclinical candidate selection. Our comprehensive service platforms and scientific expertise provide end-to-end solutions to meet the diverse needs of our clients. From small molecules, oligos, and peptides, to antibodies, cell, and gene therapies, we cover a wide range of modalities with fast turnaround times and quick study launches. Our advanced biochemical and structural biology capabilities, coupled with cutting-edge screening techniques and animal models support drug discovery research across all major target classes and disease areas, from hit ID to lead optimization and beyond.
Capabilities at a Glance
- Expertise in all major disease areas and target classes, enabling discovery for all modalities
- World class antiviral platform with an unequalled service capability and capacity in HBV, and other viral diseases
- A global leader in DNA Encoded Library (DEL) screening, with innovative business models
- CAP-certified pathology and FACS capabilities supporting clinical biomarker services
- The world’s leading integrated, on-line, tumor model database
- 1,600+ customers worldwide
- More than 2,800 employees worldwide; 9 facilities in 3 countries
Structural Biology
WuXi Biology offers structural biology services with customized and integrated solutions to advance your discovery projects
in vitro Biology
WuXi Biology offers comprehensive assays services that cover all major therapeutic target classes to support the in vitro pharmacological characterization. Our in vitro biology services include HTS, SAR screening support, compound selectivity and early safety profiling, and cancer cell panel profiling.
- High Content Platform
- High Throughput Screening
- In Vitro Assays for Diabetes and Other Metabolic Diseases
- Cancer Cell Panel & In Vitro Oncology Assays
- Radioactive Assays
- GPCR, Transporter, NHR
- Cellular Assays
- Kinase Assay
- Ion Channel
- Enzymes/Biochemical Assays
- In vitro Safety Pharmacology Profiling
- Toxicology
in vivo Pharmacology
WuXi Biology has established multiple in vivo animal models to evaluate preclinical drug candidates. Each disease model is designed to understand specific aspects of drug property and its mechanism of action.
Infectious Disease Unit
WuXi Biology provides a comprehensive infectious disease platform from assay setup to clinical trial support.
Oncology and Immuno-oncology Unit
Our innovative platform covers all research needs ranging from target discovery, in vitro and in vivo pharmacology, and translational research to clinical biomarker testing enabling drug discovery for cancer, autoimmune disease and rare genetic diseases (RGD).
